ME/CFS Science @mecfsscience.org · 17/12/20251) Prof. Scheibenbogen announced that the biopharma company Sanofi is willing to support a drug trial on ME/CFS led by the Charité. Sanofi also expressed an interest in gaining a better understanding of the disease and its mechanisms. 17525
ME/CFS Science @mecfsscience.org · 17/12/20252) Not entirely sure which drug this refers to, but Scheibenbogen previously talked about doing a trial targeting plasma cells that produce antibodies, so it could be Isatuximab (which targets the cell marker CD38, the same as Daratumumab). 2202
ME/CFS Science @mecfsscience.org · 17/12/20253) This was said during a presentation at the German Parliament (Deutscher Bundestag) on the national decade against PAIZ. There were also presentations by: - Jörg Heydecke of the ME/CFS Research Foundation - Joachim L. Schultze - Bettina Hohberger - Jürgen Michael Steinacker 1131
Andreas Longva @andlon.bsky.social · 17/12/2025Scheibenbogen also talked about drugs that target CD19 at the DGN Kongress, and it looks like some Sanofi researchers have been involved in research on CAR-T therapy targeting CD19: pubmed.ncbi.nlm.nih.gov/39655494/pubmed.ncbi.nlm.nih.govIdentifying CD19-targeted CAR-T cell immune pathways in an in vitro human immune mimetic cytokine release assay - PubMedCD19-targeted chimeric antigen receptor-modified T (CAR-T) cells have shown success in clinical studies, with several CD19 CAR-T cell products now having been approved for market use. However, this cell therapy can be associated with side effects such as cytokine release syndrome (CRS). Therefore, p … 120
